Pelthos Therapeutics (NYSEAMERICAN:PTHS) Coverage Initiated by Analysts at Cantor Fitzgerald

Stock analysts at Cantor Fitzgerald assumed coverage on shares of Pelthos Therapeutics (NYSEAMERICAN:PTHS) in a research note issued to investors on Wednesday. The firm set an “overweight” rating and a $50.00 price target on the stock. Cantor Fitzgerald’s price objective indicates a potential upside of 137.98% from the stock’s current price.

Several other brokerages have also weighed in on PTHS. Zacks Research raised shares of Pelthos Therapeutics from a “strong sell” rating to a “hold” rating in a report on Tuesday, March 24th. Roth Mkm lowered their price objective on Pelthos Therapeutics from $57.00 to $55.00 and set a “buy” rating for the company in a report on Thursday, February 26th. Piper Sandler assumed coverage on Pelthos Therapeutics in a report on Friday, February 27th. They set an “overweight” rating and a $48.00 target price on the stock. HC Wainwright reiterated a “buy” rating and issued a $60.00 price target on shares of Pelthos Therapeutics in a report on Thursday, March 19th. Finally, Oppenheimer lifted their price objective on shares of Pelthos Therapeutics from $60.00 to $62.00 and gave the stock an “outperform” rating in a report on Friday, March 20th. Five research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, Pelthos Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $55.00.

Pelthos Therapeutics Trading Up 0.0%

Shares of NYSEAMERICAN:PTHS opened at $21.01 on Wednesday. The company has a market capitalization of $70.59 million, a price-to-earnings ratio of -1.01 and a beta of 3.87. The stock has a fifty day moving average of $23.06. The company has a current ratio of 2.05, a quick ratio of 1.15 and a debt-to-equity ratio of 0.81. Pelthos Therapeutics has a 12-month low of $9.00 and a 12-month high of $54.29.

Institutional Investors Weigh In On Pelthos Therapeutics

Several large investors have recently made changes to their positions in PTHS. Persistent Asset Partners Ltd boosted its position in shares of Pelthos Therapeutics by 150.0% during the fourth quarter. Persistent Asset Partners Ltd now owns 6,007 shares of the company’s stock worth $186,000 after buying an additional 3,604 shares during the period. Millennium Management LLC acquired a new stake in Pelthos Therapeutics in the fourth quarter worth about $343,000. Geode Capital Management LLC grew its position in Pelthos Therapeutics by 31.9% in the 4th quarter. Geode Capital Management LLC now owns 13,625 shares of the company’s stock valued at $422,000 after buying an additional 3,295 shares in the last quarter. Knott David M Jr increased its stake in Pelthos Therapeutics by 215.5% during the 4th quarter. Knott David M Jr now owns 19,281 shares of the company’s stock valued at $598,000 after buying an additional 13,169 shares during the period. Finally, Diadema Partners LP raised its position in shares of Pelthos Therapeutics by 138.1% during the 4th quarter. Diadema Partners LP now owns 25,000 shares of the company’s stock worth $775,000 after buying an additional 14,502 shares in the last quarter. Institutional investors and hedge funds own 77.96% of the company’s stock.

Pelthos Therapeutics Company Profile

We are a clinical-stage biotech company focused on developing and commercializing new therapeutics to alleviate pain. Our clinical focus is to selectively target the sodium ion-channel known as “NaV1.7”, as well as other receptors in the NaV family. NaV1.7 has been genetically validated as a pain receptor in human physiology. Genetic studies have shown that families with a certain inherited NaV1.7 modulation consistently show a pathology of not feeling pain. A NaV1.7 blocker is a chemical entity that modulates the structure of the sodium-channel in a way to prevent the transmission of pain perception to the central nervous system (“CNS”).